Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50742-0484-01 50742-0484 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
51817-0586-01 51817-0586 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
54288-0109-02 54288-0109 Melphalan Hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard July 2, 2021 In Use
55150-0337-01 55150-0337 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
55150-0381-01 55150-0381 Pemetrexed Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
55150-0382-01 55150-0382 Pemetrexed Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
55150-0383-01 55150-0383 Pemetrexed Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
59651-0530-03 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0530-10 59651-0530 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-03 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0532-10 59651-0532 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
61703-0150-05 61703-0150 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0262-05 61703-0262 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
61703-0600-05 61703-0600 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 23, 2022 In Use
63323-0450-50 63323-0450 PEMETREXED DISODIUM Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0621-00 63323-0621 PEMETREXED DISODIUM Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0622-00 63323-0622 PEMETREXED DISODIUM Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
63323-0821-10 63323-0821 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 In Use
67184-0532-01 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-02 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-03 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0533-01 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0533-02 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use

Found 10,000 results in 7 milliseconds — Export these results